Denmark is the first nation in Europe—and in the world—to switch all well-treated rheumatoid arthritis patients from reference infliximab (Remicade) to the biosimilar Remsima, and 1 early study suggests that the switch has been successful. Patients, however, have needed convincing.
Denmark is the first nation in Europe—and in the world—to switch all well-treated rheumatoid arthritis patients from reference infliximab (Remicade) to the biosimilar Remsima, and 1 early study suggests that the switch has been successful.
The study, published in Annals of the Rheumatic Diseases, examined the non-medical switch of 802 Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) from the reference to the biosimilar infliximab. The researchers investigated the patients’ disease activity 3 months prior to and 3 months after the switch and subsequently measured changes over time. The 403 patients with RA, 120 patients with PsA, and 279 with AxSpA had been treated with the reference infliximab for a median duration of 6.8 years (range, 4.3 to 9.5). Follow-up was conducted at 413 days (range, 339 to 442). The researchers found that disease activities were similar 3 months before and after the switch, and concluded that the switch had no negative impact on disease activity.
The results suggest that Denmark could realize a substantial cost savings in the treatment of RA by switching patients to a lower-cost, high-quality biosimilar treatment. Yet, however willing Denmark’s health system may be to make the switch from reference to biosimilar products, Danish patients have been reluctant to switch from more familiar biologics to less expensive biosimilars.
A statement provided by the European League Against Rheumatism (EULAR) says that many patients felt anxious about the national switch to biosimilars and their concerns were exacerbated by several factors:
To address these apprehensions, the Danish Rheumatism Association (DRA), a non-governmental organization with an 80,000-person membership, engaged with politicians, medical authorities, and hospital administrations in a 4-pronged plan, which ran from August 2015 through the end of 2016, and had the following objectives:
Additionally, representatives from the DRA have participated in working groups in hospitals across the nation’s regions with the objective of including the patient perspective in future national recommendations concerning biological drugs, biosimilars, and switching.
The US healthcare system differs significantly from the government-sponsored Danish system, in which patients could be made to switch treatments unless a medically justified reason prevented treatment with the biosimilar. In the United States, patients may have more say in their own treatment protocols, and may prove reluctant to switch treatments if they do not feel that biosimilars provide as much safety and efficacy as they do affordability. Manufacturers, payers, and other stakeholders seeking to drive biosimilar uptake in the United States may wish to look to the DRA’s example in advocating for and facilitating greater education and safety monitoring as a means of alleviating patient concerns.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.